TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05404633

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ergogycle prototype testing for acceptability
Description: The objective was to assess the acceptability of the ergogycle prototype (device) while used in a clinical settings by both the patients and the professionals.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ergogycle prototype testing for acceptability
Description: The objective was to assess the acceptability of the ergogycle prototype (device) while used in a clinical settings by both the patients and the professionals.
Study: NCT05206786

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional preventive work out
Description: Female players in the control group will carry out a conventional preventive work that is organised in 3 training days per week. First training session includes preventive strength and proprioception exercises. Junior and senior teams (above 16 years old) will also do plyometrics exercises. In the second training session, players will do preventive strength exercises with an increased load compared to the previous session and proprioception exercises. Junior and senior players will also do anaerobic work. In the third session, players will perform reaction speed exercises.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional preventive work out
Description: Female players in the control group will carry out a conventional preventive work that is organised in 3 training days per week. First training session includes preventive strength and proprioception exercises. Junior and senior teams (above 16 years old) will also do plyometrics exercises. In the second training session, players will do preventive strength exercises with an increased load compared to the previous session and proprioception exercises. Junior and senior players will also do anaerobic work. In the third session, players will perform reaction speed exercises.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gluteus maximus strengthening specific program
Description: Female players will carry out a gluteus maximus strengthening work out in addition to the control group programme. Of the following four exercises, the first and the third ones will be done on the first training session and the second and the fourth exercises will be done on the second one. Dosage will be 2 sets of 10 repetitions for each leg.~1. Clam Shell: Lateral decubitus with the knees and hips bend, the working leg placed on top of the other. Separate this knee while feet stay in contact.~2. Unilateral gluteal bridge: Supine decubitus with one foot flat on the floor and bent knee. This leg pushes the ground with the foot until the pelvis is lifted while the other leg remains straight.~3. Quadruped hip extension with knee extension : Quadruped on forearms. Straighten the hip by bringing the whole leg up and back with knee extension.~4. Quadruped hip extension with bent knee: Performed as the previous one, but during this one, the knee of the working leg is bent at 90º.
Study: NCT06482619

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Creatine supplementation
Description: The supplements were provided in capsules of 1 g of red color not transparent Guinama S.L.U, 0044634, La Pobla de Valbona, Spain) which were prepared with a Capsunorm 2000 semi-automatic manual capsule filling machine (Miranda del Ebro, Spain). Capsules contained creatine monohidrate (Creapure, Crown Sport Nutrition, Arnedo, Spain)

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The supplements were provided in capsules of 1 g of red color not transparent Guinama S.L.U, 0044634, La Pobla de Valbona, Spain) which were prepared with a Capsunorm 2000 semi-automatic manual capsule filling machine (Miranda del Ebro, Spain). Capsules contained placebo (i.e., sucrose)
Study: NCT05772507

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: URGO AWC_008 dressing or URGO AWC_022 dressing
Description: local management of acute or chronic wounds
Study: NCT05096598

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZP8396
Description: Participants will receive 1 single dose of ZP8396 given subcutaneously (s.c., under the skin) or intravenously (i.v., in a vein of the arm). Dose level will depend on the cohort.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (ZP8396)
Description: Participants will receive 1 single dose of placebo given subcutaneously (s.c., under the skin) or intravenously (i.v., in a vein of the arm).
Study: NCT05277389

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: START - Startle Adjuvant Rehabilitation Therapy
Description: Application of startling acoustic stimuli during practice of movement task

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Control
Description: Practice of Movement task without START
Study: NCT06188845

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kinesio taping
Description: Kinesio taping is a non-invasive physical treatment, which is breathable, hypoallergenic and elastic. Because of the mechanical properties and physiological effects, Kinesio taping has been thought to relieve pain, reduce swelling, support and relax soft tissue, promote motor performance, and correct posture or abnormal movement patterns.
Study: NCT05363813

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: M/L-10 Multi-Fire Clip Applier and M/L-10 Clip Cartridge (Multi-Fire Clip System)
Description: Permanent ligation of vessels and ducts as part of minimally invasive laparoscopic surgery.
Study: NCT04617964

Intervention type: OTHER
Intervention: Ultrasound
Description: Assessment the intra and interoperator reproducibility of the measurement of the right portal vein diameter at the routine third trimester ultrasound

Intervention type: OTHER
Intervention: Ultrasound
Description: Assessment the intra and interoperator reproducibility of the measurement of the right portal vein diameter at the routine third trimester ultrasound
Study: NCT05409508

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mindfulness meditation care
Description: mindfulness meditation care

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: no mindfulness meditation care
Description: no mindfulness meditation care
Study: NCT05235971

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Episodic Future thinking
Description: During a visit with the study team, participants will identify personally-relevant reminders, or cues, that they will receive up to 3 messages a day via text-message over a two-week period.~The messages will describe positive, non-alcohol related events at future time points to facilitate extension of temporal consideration toward future-focused perspectives.~In addition, participants will have phone meetings (video or not) where health behaviors as well as survey information is noted and collected

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Episodic Future thinking
Description: During a visit with the study team, participants will identify personally-relevant reminders, or cues, that they will receive up to 3 messages a day via text-message over a two-week period.~The messages will describe positive, non-alcohol related events at future time points to facilitate extension of temporal consideration toward future-focused perspectives.~In addition, participants will have phone meetings (video or not) where health behaviors as well as survey information is noted and collected

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Volitional choice
Description: Volitional choice creates structured if-then plans to dismantle context-linked alcohol use The messages sent over a two-week period facilitate alternative, healthier choices by identifying and linking risky cues with alternative actions. Participants will receive up to 3 messages a day for 14 days that include assessment and intervention messages.~In addition, participants will have phone meetings (video or not) where health behaviors as well as survey information is noted and collected.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Volitional choice
Description: Volitional choice creates structured if-then plans to dismantle context-linked alcohol use The messages sent over a two-week period facilitate alternative, healthier choices by identifying and linking risky cues with alternative actions. Participants will receive up to 3 messages a day for 14 days that include assessment and intervention messages.~In addition, participants will have phone meetings (video or not) where health behaviors as well as survey information is noted and collected.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Monitoring only
Description: Participants will receive general psychoeducation about alcohol use, mental health, resources, and a description of the assessments to be completed over a two-week field testing period.~In addition, participants will have phone meetings (video or not) where health behaviors as well as survey information is noted and collected.
Study: NCT06434688

Intervention type: OTHER
Intervention: Mental Fatigue:
Description: The Mental Fatigue Scale (MFS) will be used to assess mental fatigue.

Intervention type: OTHER
Intervention: Mental Fatigue:
Description: The Mental Fatigue Scale (MFS) will be used to assess mental fatigue.

Intervention type: OTHER
Intervention: Body Awareness:
Description: Individuals' general body awareness will be assessed with the Body Awareness Questionnaire (BAQ).~Neck awareness of individuals will be assessed with the Fremantle Neck Awareness Questionnaire (FreBFA).~Short Form of the Five Facet Mindfulness Questionnaire (FFMQ - Short Form) will be used to assess people's mindfulness.~- In-body awareness:~For the sense of interoception, the Multidimensional Assessment of Interoceptive Awareness Scale, which assesses interoceptive body awareness, will be used.~To evaluate proprioception, a Cervical Range of Motion (CROM) device is used.~The bucket test will be used to assess subjective visual verticality, which is one of the sub-dimensions of verticality perception.~Two scales will be used to assess people's awareness of weight transfer symmetry.~- Out of Body Awareness:~Right-Left Confusion Hand Test will be used to evaluate the mental rotation skill within the scope of the sense of extroception.

Intervention type: OTHER
Intervention: Body Awareness:
Description: Individuals' general body awareness will be assessed with the Body Awareness Questionnaire (BAQ).~Neck awareness of individuals will be assessed with the Fremantle Neck Awareness Questionnaire (FreBFA).~Short Form of the Five Facet Mindfulness Questionnaire (FFMQ - Short Form) will be used to assess people's mindfulness.~- In-body awareness:~For the sense of interoception, the Multidimensional Assessment of Interoceptive Awareness Scale, which assesses interoceptive body awareness, will be used.~To evaluate proprioception, a Cervical Range of Motion (CROM) device is used.~The bucket test will be used to assess subjective visual verticality, which is one of the sub-dimensions of verticality perception.~Two scales will be used to assess people's awareness of weight transfer symmetry.~- Out of Body Awareness:~Right-Left Confusion Hand Test will be used to evaluate the mental rotation skill within the scope of the sense of extroception.
Study: NCT06133686

Intervention type: DRUG
Group type: OTHER
Intervention: Tenofovir disoproxil fumarate/emtricitabine (TDF-FTC), cabotegravir (CAB-LA)
Description: Group A will receive oral TDF-FTC PrEP (using either event-driven or daily) for 9-months. After 9-months, participants will be offered choice of PrEP (either TDF-FTC or CAB-LA) for a further 9-months, with the ability to change choice as required. Those receiving oral PrEP will be able to choose between event-driven and daily PrEP with the emphasis on coital coverage by PrEP

Intervention type: DRUG
Group type: OTHER
Intervention: Cabotegravir (CAB-LA), Tenofovir disoproxil fumarate/emtricitabine (TDF-FTC)
Description: Group B will receive CAB-LA for 9-months. After 9-months participants will be offered choice of PrEP (either TDF-FTC or CAB-LA) for a further 9-months, with the ability to change choice as required. Those receiving oral PrEP will be able to choose between event-driven and daily PrEP with the emphasis on coital coverage by PrEP.
Study: NCT05423106

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-64457744
Description: JNJ-64457744 will be administered as oral solution.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-64457744
Description: JNJ-64457744 will be administered as oral solution.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-64457744
Description: JNJ-64457744 will be administered as oral solution.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-64457744
Description: JNJ-64457744 will be administered as oral solution.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-64457744
Description: JNJ-64457744 will be administered as oral solution.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-64457744
Description: JNJ-64457744 will be administered as oral solution.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be administered as an oral formulation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be administered as an oral formulation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be administered as an oral formulation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be administered as an oral formulation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be administered as an oral formulation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir Disoproxil Fumarate (TDF)
Description: TDF tablet will be administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir Alafenamide (TAF)
Description: TAF tablet will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entecavir (ETV)
Description: ETV tablet will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-64457744
Description: JNJ-64457744 will be administered as oral tablet.
Study: NCT05316909

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Breastfeeding Simulation
Description: In Period 1, one group will begin a simulated session with the NORALSim and the second group will begin with either the Mother's Own Milk Lactessa or Laerdal NeoNatalie, depending on the study date. Baseline level of breastfeeding experience and clinical lactation skills self-efficacy will be collected. Nursing students will teach a mock patient wearing the LSM and holding a newborn simulator how to position and attach the newborn at the breast and identify effective breastfeeding by differentiating between suckling patterns. In Period 2, each group will crossover to complete the same session with a different newborn simulator. After Period 1, each group will debrief to discuss their performance and engagement and use a Qualtrics survey (6-point Likert scale) to rate satisfaction, engagement, simulator fidelity, and self-efficacy. The same quantitative and qualitative data collection protocol will follow Period 2.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Breastfeeding Simulation
Description: In Period 1, one group will begin a simulated session with the NORALSim and the second group will begin with either the Mother's Own Milk Lactessa or Laerdal NeoNatalie, depending on the study date. Baseline level of breastfeeding experience and clinical lactation skills self-efficacy will be collected. Nursing students will teach a mock patient wearing the LSM and holding a newborn simulator how to position and attach the newborn at the breast and identify effective breastfeeding by differentiating between suckling patterns. In Period 2, each group will crossover to complete the same session with a different newborn simulator. After Period 1, each group will debrief to discuss their performance and engagement and use a Qualtrics survey (6-point Likert scale) to rate satisfaction, engagement, simulator fidelity, and self-efficacy. The same quantitative and qualitative data collection protocol will follow Period 2.
Study: NCT04847310

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Group brief transdiagnostic cognitive-behavioral therapy
Description: An adaptation of the Unified Protocol for the Transdiagnostic Treatment of Emotional Disorders (UP) (Barlow et al., 2015) and the IAPT programme (Clark, 2018). It has been developed by Cano-Vindel (González-Blanch et al., 2018) and consists in seven 90-minute sessions, provided by a non-assessor clinical psychologist in 12-16 weeks, with 8-10 participants per group. Sessions are weekly or biweekly, reducing their frequency as the intervention advances. The activities and homework proposed are supported with materials such as theory documents, a CD for progressive muscle relaxation, self-recording sheets, and a therapy web (www.desordenesemocionales.es).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Individual brief transdiagnostic cognitive-behavioral therapy
Description: An adaption of the group therapy, with the same phases. However, since it is an individual intervention, it is more flexible than group one and its contents and duration can be personalized. This intervention consists of a minimum of 6 and a maximum of 8 sessions of 30-60 minutes, provided by a clinical psychologist not involved in the assessments.
Study: NCT06434688

Intervention type: OTHER
Intervention: Neck Disability Level
Description: Neck disability index will be used to assess this parameter.

Intervention type: OTHER
Intervention: Quality Of Life
Description: SF-12 will be used to assess quality of life.

Intervention type: OTHER
Intervention: Quality Of Life
Description: SF-12 will be used to assess quality of life.

Intervention type: OTHER
Intervention: Pain Assessment:
Description: Pain intensity will be assessed by Visual Analog Scale (VAS). In addition, pain duration and pain frequency will be questioned. The Pain Self-Efficacy Questionnaire will be used to assess the confidence of people with chronic pain to perform certain tasks and behaviors despite their pain.

Intervention type: OTHER
Intervention: Physical Condition:
Description: Normal range of motion of the cervical region will be evaluated with the Cervical Range of Motion device.~New York Posture Rating Scale will be used to evaluate posture.~Symmetry of weight transfer to both lower extremities of the individuals in standing upright position will be evaluated.

Intervention type: OTHER
Intervention: Physical Condition:
Description: Normal range of motion of the cervical region will be evaluated with the Cervical Range of Motion device.~New York Posture Rating Scale will be used to evaluate posture.~Symmetry of weight transfer to both lower extremities of the individuals in standing upright position will be evaluated.

Intervention type: OTHER
Intervention: Anxiety and Depression:
Description: Beck Depression and Beck Anxiety scales will be used to assess depression and anxiety.

Intervention type: OTHER
Intervention: Anxiety and Depression:
Description: Beck Depression and Beck Anxiety scales will be used to assess depression and anxiety.
Study: NCT05683925

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Noninvasive transcutaneous auricular vagus nerve stimulation at 100Hz
Description: Noninvasive electrostimulation will be applied to the left cyma conchae through the Nemos® electrode with the following parameters: square-shaped pseudobiphasic pulse, interpulse duration 80μs, pulse width 300μs, pulse intensity 0,1mA above the perceptual threshold at 100Hz. The intensity for each separate stimulation will be adjusted for each participant at the beginning of the experiment.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Noninvasive transcutaneous auricular vagus nerve stimulation at 25Hz
Description: Noninvasive electrostimulation will be applied to the left cyma conchae through the Nemos® electrode with the following parameters: square-shaped pseudobiphasic pulse, interpulse duration 80μs, pulse width 300μs, pulse intensity 0,1mA above the perceptual threshold at 25Hz. The intensity for each separate stimulation will be adjusted for each participant at the beginning of the experiment.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Noninvasive transcutaneous earlobe stimulation at 25Hz
Description: Noninvasive electrostimulation will be applied to the left earlobe through the Nemos® electrode with the following parameters: square-shaped pseudobiphasic pulse, interpulse duration 80μs, pulse width 300μs, pulse intensity 0,1mA above the perceptual threshold at 25Hz. The intensity for each separate stimulation will be adjusted for each participant at the beginning of the experiment.
Study: NCT06512883

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Benralizumab
Description: Benralizumab will be administered as SC injection on Q4W.
Study: NCT04475718

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Fourth Trimester Mobile Tool
Description: A mobile web-based tool for underserved women in the fourth trimester. The mobile platform teaches self-efficacy, care management, and coping skills to help reduce major health risks and provide tools and resources to maintain mental health.
Study: NCT05058092

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Immediate Remedee Solution
Description: * D0 to M3: Remedee Solution + medical care~* M3 to M6: Remedee Solution without personalized support + medical care~* M6 to M9: medical care only

Intervention type: DEVICE
Group type: OTHER
Intervention: Delayed Remedee Solution
Description: * D0 to M3: medical care only~* M3 to M6: Remedee Solution + medical care~* M6 to M9: Remedee Solution without personalized support + medical care
Study: NCT05253118

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: Tislelizumab (BGB-A317) 200mg will be administered on Day 1 of each 21-day cycle (once every 3 weeks) in combination with pemetrexed.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Pemetrexed 500 mg/m2 will be administered on Day 1 of each 21-day cycle (once every 3 weeks).